Skip to main content
. 2020 Jan 2;117(3):1321–1329. doi: 10.1073/pnas.1915202117

Fig. 5.

Fig. 5.

Peroxiredoxin III PRDX3 as a target of AuMesoIX. (A) Thermal stabilization of PRDX3 following treatment of A2780 ovarian cancer cells with AuMesoIX as determined by CETSA. (B) Mass spectra of the adducts formed between AuMesoIX and peptides of PRDX3 containing different active-site cysteines; red square indicates the modification site of AuMesoIX. (C) Dose-dependent effect of AuMesoIX on recombinant PRDX3 activity as measured by NADPH-dependent hydrogen peroxide reduction via a coupled Trx/Trx reductase (TrxR) system. (D) Immunoblotting analysis of PRDX3 expression in cells treated with indicated concentrations of AuMesoIX for 8 h. (E) Immunofluorescence staining of PRDX3 (green) and COXIV (red) in cells treated with AuMesoIX or DMSO vehicle. Nuclei were stained with DAPI (blue). (F and G) Flow cytometry analysis of intracellular oxidants of cells treated with AuMesoIX (3 μM) for 8 h as examined by (F) DCFH-DA or (G) MitoPY1 probe.